scholarly journals Role of Hyperbaric Oxygenation Plus Hypofractionated Stereotactic Radiotherapy in Recurrent High-Grade Glioma

2021 ◽  
Vol 11 ◽  
Author(s):  
Donatella Arpa ◽  
Elisabetta Parisi ◽  
Giulia Ghigi ◽  
Annalisa Cortesi ◽  
Pasquale Longobardi ◽  
...  
Keyword(s):  
Stereotactic Radiotherapy ◽  
Oxygen Deficiency ◽  
Progression Free Survival ◽  
High Grade Glioma ◽  
High Grade ◽  
Clinical Trial Registration ◽  
Hypofractionated Stereotactic Radiotherapy ◽  
Tumour Control ◽  
Local Tumour Control ◽  
Local Tumour

BackgroundThe presence of hypoxic cells in high-grade glioma (HGG) is one of major reasons for failure of local tumour control with radiotherapy (RT). The use of hyperbaric oxygen therapy (HBO) could help to overcome the problem of oxygen deficiency in poorly oxygenated regions of the tumour. We propose an innovative approach to improve the efficacy of hypofractionated stereotactic radiotherapy (HSRT) after HBO (HBO-RT) for the treatment of recurrent HGG (rHGG) and herein report the results of an ad interim analysis.MethodsWe enrolled a preliminary cohort of 9 adult patients (aged >18 years) with a diagnosis of rHGG. HSRT was administered in daily 5-Gy fractions for 3-5 consecutive days a week. Each fraction was delivered up to maximum of 60 minutes after HBO.ResultsMedian follow-up from re-irradiation was 11.6 months (range: 3.2-11.6 months). The disease control rate (DCR) 3 months after HBO-RT was 55.5% (5 patients). Median progression-free survival (mPFS) for all patients was 5.2 months (95%CI: 1.34-NE), while 3-month and 6-month PFS was 55.5% (95%CI: 20.4-80.4) and 27.7% (95%CI: 4.4-59.1), respectively. Median overall survival (mOS) of HBO-RT was 10.7 months (95% CI: 7.7-NE). No acute or late neurologic toxicity >grade (G)2 was observed in 88.88% of patients. One patient developed G3 radionecrosis.ConclusionsHSRT delivered after HBO appears to be effective for the treatment of rHGG, it could represent an alternative, with low toxicity, to systemic therapies for patients who cannot or refuse to undergo such treatments.Clinical Trial Registrationwww.ClinicalTrials.gov, identifier NCT 03411408.

scholarly journals P13.03 * HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY (HSR) IN RECURRENT HIGH GRADE GLIOMA: A SAFE AND EFFECTIVE APPROACH

2014 ◽  
Vol 16 (suppl 2) ◽  
pp. ii66-ii66
Author(s):  
A. Ascolese ◽  
F. Pessina ◽  
P. Navarria ◽  
S. Tomatis ◽  
P. Mancosu ◽  
...  
Keyword(s):  
Stereotactic Radiotherapy ◽  
High Grade Glioma ◽  
High Grade ◽  
Hypofractionated Stereotactic Radiotherapy

Nuklearmedizin trifft Strahlentherapie

2010 ◽  
Vol 49 (S 01) ◽  
pp. S11-S15
Author(s):  
C. Schütze ◽  
M. Krause ◽  
A. Yaromina ◽  
D. Zips ◽  
M. Baumann
Keyword(s):  
Nuclear Medicine ◽  
Radiation Oncology ◽  
External Beam Radiotherapy ◽  
Biological Knowledge ◽  
Important Research ◽  
Tumour Control ◽  
Research Areas ◽  
Normal Tissue Damage ◽  
Local Tumour Control ◽  
Local Tumour

SummaryRadiobiological and cell biological knowledge is increasingly used to further improve local tumour control or to reduce normal tissue damage after radiotherapy. Important research areas are evolving which need to be addressed jointly by nuclear medicine and radiation oncology. For this differences of the biological distribution of diagnostic and therapeutic nuclides compared with the more homogenous dose-distribution of external beam radiotherapy have to be taken into consideration. Examples for interdisciplinary biology-based cancer research in radiation oncology and nuclear medicine include bioimaging of radiobiological parameters characterizing radioresistance, bioimage-guided adaptive radiotherapy, and the combination of radiotherapy with molecular targeted drugs.

PO-1926 Enhanced local tumour control by combining proton radiation and immunotherapy

2021 ◽  
Vol 161 ◽  
pp. S1642
Author(s):  
M. Horsman ◽  
S. Nielsen ◽  
M. Sitarz ◽  
M. Høyer ◽  
B. Sørensen
Keyword(s):  
Proton Radiation ◽  
Tumour Control ◽  
Local Tumour Control ◽  
Local Tumour

Comparing plaque brachytherapy and proton therapy for choroidal melanoma: a review of the literature

2010 ◽  
Vol 9 (1) ◽  
pp. 53-61
Author(s):  
Jeremy P. Appleton ◽  
Peter Bridge
Keyword(s):  
Conservative Treatment ◽  
Proton Therapy ◽  
Normal Tissue ◽  
Treatment Options ◽  
Choroidal Melanoma ◽  
Review Of The Literature ◽  
Tumour Control ◽  
Local Tumour Control ◽  
Local Tumour ◽  
Plaque Brachytherapy

AbstractThe aims of conservative treatment in patients with ocular melanoma are globe retention, good visual acuity (VA) and local control. Two well-established radiation conservative treatment options are proton beam radiotherapy and episcleral plaque brachytherapy (EPB). Patients who receive treatment with either of these options will experience some degree of radiation-related ocular complications and poor VA. The purpose of this review of the literature is to establish whether there is a significant clinical difference in normal tissue morbidity and local tumour control between proton therapy and EPB, and whether this difference can justify the purchase and implementation of additional proton therapy facilities. Based on this review, evidence suggested that both treatment options are comparable, and that neither proton therapy nor EPB is clinically superior than the other regarding normal tissue morbidity and local tumour control. This review highlighted the need for further research on a larger scale in order to bridge the gap that is apparent within the literature.

scholarly journals Extensive systemic metastases from primary central nervous system haemangiopericytoma

2020 ◽  
Vol 6 (2) ◽  
pp. 20190081
Author(s):  
Chi Long Ho ◽  
Jeremy JH Lam ◽  
Robert Chun Chen
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Fatal Outcome ◽  
Imaging Features ◽  
Tumour Control ◽  
Local Tumour Control ◽  
Meningeal Tumour ◽  
Local Tumour ◽  
The Central Nervous System ◽  
Extracranial Metastases

Primary intracranial tumours rarely metastasise outside of the central nervous system (CNS). This report describes a rare case of recurrent meningeal haemangiopericytoma with extensive systemic metastases, which eventually resulted in a fatal outcome. We discuss some prevailing theories as to the rarity of extracranial metastases from primary CNS haemangiopericytoma, and elucidate the epidemiology, imaging features, differential diagnosis, treatment, and prognosis of this unusual but surprisingly aggressive meningeal tumour. Besides aggressive treatment for local tumour control, patients with primary CNS haemangiopericytoma require long-term post-treatment surveillance to detect systemic metastases.

scholarly journals An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
M. Huylebrouck ◽  
S. Lv ◽  
J. Duerinck ◽  
A. Van Binst ◽  
I. Salmon ◽  
...  
Keyword(s):  
Phase Ii ◽  
Tumor Response ◽  
Metabolic Response ◽  
Objective Response ◽  
Progression Free Survival ◽  
High Grade Glioma ◽  
High Grade ◽  
University Hospitals ◽  
Phase Ii Trials ◽  
Antiangiogenic Effect

Background. Bevacizumab (BEV), a humanized immunoglobulin G1 monoclonal antibody that inhibits VEGF has demonstrated activity against recurrent high-grade gliomas (HGG) in phase II clinical trials.Patients and Methods. Data were collected from patients with recurrent HGG who initiated treatment with BEV outside a clinical trial protocol at two Belgian university hospitals.Results. 19 patients (11 M/8 F) were administered a total of 138 cycles of BEV (median 4, range 1–31). Tumor response assessment by MRI was available for 15 patients; 2 complete responses and 3 partial responses for an objective response rate of 26% for the intent to treat population were observed on gadolinium-enhanced T1-weighted images; significant regressions on T2/FLAIR were documented in 10 out of 15 patients (67%). A reduced uptake on PET was documented in 3 out of 4 evaluable patients. The six-month progression-free survival was 21% (95% CI 2.7–39.5). Two patients had an ongoing tumor response and remained free from progression after 12 months of BEV treatment.Conclusions. The activity and tolerability of BEV were comparable to results from previous prospective phase II trials. Reduced uptake on PET suggests a metabolic response in addition to an antiangiogenic effect in some cases with favorable clinical outcome.

Residual γH2AX foci predict local tumour control after radiotherapy

2013 ◽  
Vol 108 (3) ◽  
pp. 434-439 ◽  
Author(s):  
Ulrike Koch ◽  
Katharina Höhne ◽  
Cläre von Neubeck ◽  
Howard D. Thames ◽  
Ala Yaromina ◽  
...  
Keyword(s):  
Tumour Control ◽  
Γh2ax Foci ◽  
Local Tumour Control ◽  
Local Tumour

PATH-41. POLYMORPHOUS LOW-GRADE NEUROEPITHELIAL TUMOR OF THE YOUNG WITH FGFR3-TACC3 FUSION MIMICKING HIGH-GRADE GLIOMA: CASE REPORT AND SERIES OF HIGH-GRADE CORRELATES

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi124-vi124
Author(s):  
Danielle Golub ◽  
Peter C Pan ◽  
Benjamin Liechty ◽  
Cheyanne Slocum ◽  
Tejus Bale ◽  
...  
Keyword(s):  
Progression Free Survival ◽  
High Grade Glioma ◽  
Proliferation Index ◽  
Molecular Profile ◽  
Low Grade ◽  
High Grade ◽  
Molecular Features ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Promoter Mutations

Abstract BACKGROUND Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a recently-described entity that can occasionally histologically and molecularly mimic high-grade glioma. The histologic and molecular features that predict aggressive behavior in FGFR3-TACC3 altered tumors are unclear. CASES We present a rare case of an indolent neuroepithelial neoplasm in a 59-year-old female with imaging initially suggestive of high-grade glioma and analyze common molecular features between this case and a series of high-grade gliomas. After total resection, pathology of the case patient revealed predominantly low-grade cytomorphology, abundant microcalcifications, unusual neovascularization, and a low proliferation index. The lesion was diffusely CD34 immunoreactive and harbored both an FGFR3-TACC3 fusion and a TERT promoter mutation. Based on the overall histologic and molecular profile, a diagnosis of PLNTY was favored. The patient was thereafter observed without adjuvant therapy with no evidence of progression at 15-month follow-up. In contrast, a series of eight adult patients with glioblastomas harboring FGFR3-TACC3 fusions and correspondingly aggressive clinical courses are also presented. Common molecular findings included IDH-wildtype status, absence of 1p19q codeletion, and CDKN2A loss. TERT promoter mutations and lack of MGMT promoter methylation were also frequently observed. These patients demonstrated a median 15-month overall survival and a 6-month progression-free survival. CONCLUSIONS PLNTY is a rare low-grade entity that can display characteristics of high-grade glioma, particularly in adults. The potential for a unique entity mimicking PLNTY which may act as a precursor lesion for a more malignant phenotype should be considered in cases with FGFR3-TACC3 fusions and other high-grade features.

Nd:YAG laser in penile diseases. Indications and limits

1996 ◽  
Vol 63 (1) ◽  
pp. 86-90
Author(s):  
E. Dotti ◽  
F. Gaboardi ◽  
A. Bozzola ◽  
T. Zago ◽  
L. Galli
Keyword(s):  
Nd:Yag Laser ◽  
Local Anaesthesia ◽  
Penile Cancer ◽  
Early Stage ◽  
Western World ◽  
Tumour Control ◽  
Local Tumour Control ◽  
Good Cosmetic ◽  
Local Tumour ◽  
Penile Diseases

— Penile cancer is an uncommon malignancy in the western world (1–2% of all malignancies in males). Traditionally it is treated by penis amputation. Today with laser therapy a new opportunity is offered. 16 patients referred to our Dept. for early stage penile cancer. 2 TIS, 7 T1, 1 T2 penile cancer and 6 with Erythroplasia of Queyrat. Before treatment the patients underwent cold biopsy in order to establish the tumour grading and staging of malignancy. A laser irradiation was performed under local anaesthesia using 25–35 Watt/3 sec in the penile cancer and 15–20 Watt/2 sec in the Erytroplasia of Queyrat. There were no complications after treatment. All patients were observed during follow-up every month after the irradiation until the sixth month and then every 3 months. No-one developed local recurrence or metastatic disease: Nd:YAG laser seems to offer a safe, easy treatment compared to traditional surgery. It can be performed under local, anaesthesia without bleeding, permits good local tumour control, a good cosmetic aspect and, finally full functionality of the penis.

Sign in / Sign up

Export Citation Format

Share Document